SWOG Cancer Research Network

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, SWOG Cancer Research Network sits in the top decile of US sponsors by registered trial count (#125 of 15,742 sponsors by registered trial count).

270 total trials 28 currently recruiting 181 completed early-phase tilt top decile by trial count

SWOG Cancer Research Network: 270 sponsored US clinical trials, 28 recruiting.

SWOG Cancer Research Network sponsors 270 registered US clinical trials on ClinicalTrials.gov, 28 of them currently recruiting, and 181 completed. 68 of these trials are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lung Cancer, with 10 trials.

Top-decile sponsor footprint

SWOG Cancer Research Network ranks in the top decile of sponsors by registered trial count (#125 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

181 of 221 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

270 total, page 3 of 6

COMPLETED Phase 3

S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo

NCT00775645
TERMINATED Phase 3

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

NCT00946712
COMPLETED Phase 2

S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

NCT00822120
COMPLETED Phase 2

S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

NCT00770224
COMPLETED Phase 2

S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer

NCT00686166
COMPLETED Phase 2

S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct

NCT00789958
COMPLETED Phase 2

S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00661193
COMPLETED

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

NCT00874211
COMPLETED Phase 2

S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery

NCT00770120
COMPLETED Phase 2

S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer

NCT00792701
COMPLETED Phase 3

S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000

NCT00706121
COMPLETED Phase 2

S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

NCT00551460
COMPLETED Phase 3

S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

NCT00445601
COMPLETED Phase 2

S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer

NCT00445848
COMPLETED Phase 2

S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma

NCT00436332
COMPLETED Phase 3

S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia

NCT00492856
COMPLETED Phase 2

S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00433446
COMPLETED Phase 2

S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone

NCT00410813
COMPLETED Phase 2

S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin

NCT00234039
COMPLETED Phase 2

S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT00337168
COMPLETED Phase 3

S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo

NCT00382018
COMPLETED Phase 1

S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00352443
COMPLETED Phase 2

S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT00376961
COMPLETED Phase 3

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

NCT00134056
COMPLETED

S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313

NCT00896727
COMPLETED

S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil

NCT00897091
TERMINATED Phase 2

S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00265785
TERMINATED Phase 2

S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery

NCT00335959
TERMINATED Phase 1

S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00288054
TERMINATED Phase 3

S0427, Combination Chemotherapy & RT in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx

NCT00268372
COMPLETED Phase 2

S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

NCT00107380
COMPLETED

S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00450281
COMPLETED Phase 2

S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

NCT00233987
COMPLETED Phase 2

S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma

NCT00107419
COMPLETED Phase 2

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

NCT00109928
TERMINATED

S0437 Long-Term Follow-Up of Patients Who Were Diagnosed With Prostate Cancer on PCPT

NCT00288106
COMPLETED Phase 2

S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer

NCT00107276
TERMINATED Phase 2

S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00124579
TERMINATED Phase 2

S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma

NCT00121186
COMPLETED Phase 2

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

NCT00104988
TERMINATED Phase 2

S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer

NCT00109850
COMPLETED Phase 2

S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00109837
TERMINATED Phase 2

S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma

NCT00109889
COMPLETED

SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma

NCT01000558
COMPLETED Phase 2

S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer

NCT00100789
COMPLETED Phase 2

S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone

NCT00096213
COMPLETED Phase 3

S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma

NCT00064038
TERMINATED Phase 2

S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women

NCT00088972
COMPLETED Phase 2

S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

NCT00096031
TERMINATED Phase 2

S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)

NCT00058448
← Previous Page 3 of 6 Next →

Phase Distribution

PhaseTrial count
Phase 1 9
Phase 2 155
Phase 3 68

Therapeutic Areas

Lung Cancer 10
Breast Cancer 7
Stage IV Lung Cancer AJCC v8 7
Leukemia 6
Recurrent Lung Non-Small Cell Carcinoma 6
Stage IV Squamous Cell Lung Carcinoma AJCC v7 4
Recurrent Squamous Cell Lung Carcinoma 4
Prostate Cancer 4
Stage IVB Lung Cancer AJCC v8 3
Stage IVA Lung Cancer AJCC v8 3

What is open in the SWOG Cancer Research Network pipeline

28 recruiting of 270 indexed (10% open); 181 completed (67%).

Phase mix: 68 late (III/IV) vs 164 early (I/II) (early-phase heavy).

Top condition: Lung Cancer (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

SWOG Cancer Research Network: open-pipeline peers nationwide

Peers matched on 270 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

SWOG Cancer Research Network sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300 0%5%10%15% Total trials Recruiting share SWOG Cancer Research NetworkAlcon ResearchNovartisAbbott Medical DevicesBoston Scientific CorporationCalifornia Pacific Medical Center Research InstituteNational Institute of Environmental Health Sciences (NIEHS)University of Rhode IslandUniversity of Mississippi Medical Center
SWOG Cancer Research Network sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

SWOG Cancer Research Network sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 270 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this SWOG Cancer Research Network page

270 registered trials is a research-attention snapshot, not an endorsement of SWOG Cancer Research Network or any single study.

  • 28 of SWOG Cancer Research Network's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Lung Cancer is the condition SWOG Cancer Research Network studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lung Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. SWOG Cancer Research Network pipeline card: 270 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.